Breakthrough Stem Cell Therapy Reverses Diabetes by Reprogramming the Immune System
For more than a century, people with Type 1 diabetes (T1D) have relied on insulin to survive — but insulin does not stop the immune system from continuing its attack on the body's insulin-producing cells. Now, researchers at the Medical University of South Carolina (MUSC) report an experimental stem cell therapy that reversed newly diagnosed T1D in a mouse model by targeting the underlying cause.
How It Works
The therapy is based on mesenchymal stem/stromal cells (MSCs), adult stem cells that can help repair tissue and regulate immune activity. The MUSC team engineered MSCs to produce alpha-1 antitrypsin (AAT), a protective protein that helps defend against inflammation. These modified AAT-MSCs work in two ways at once: protecting surviving insulin-producing cells in the pancreas while reducing the overactive immune attack.
Reprogramming, Not Just Suppressing
After treatment, the team observed a sharp rise in protective T-regulatory cells (the immune system's peacekeepers) and a drop in attacking CD8+ killer T-cells. Remarkably, the attacker cells appeared to have been pushed into exhaustion by the therapy. Even more striking: the stem cells disappeared from the body within hours or days, yet the immune system changes continued — suggesting the cells release microscopic factors that keep protecting organs long after they're gone.
A New Direction for Diabetes Care
"While insulin injections are lifesaving, they cannot stop immune attacks, and they do not prevent long-term complications," said Dr. Hongjun Wang, the study's lead author. "This study suggests a new way to treat Type 1 diabetes by addressing the root cause — immune system dysfunction — rather than just managing blood sugar."
The study, published in Molecular Therapy, focused on newly diagnosed diabetes — a period when patients are more likely to still have salvageable insulin-producing cells. The team is now evaluating the safety and effectiveness in a clinical trial with newly diagnosed T1D patients.
Beyond Diabetes
The findings could have relevance beyond diabetes. Wang and her colleagues are already studying whether a similar immune reprogramming approach could work for other autoimmune diseases, including lupus and chronic pancreatitis. The research marks a pivotal move away from managing blood sugar through daily injections toward a lasting way to reprogram the immune system itself.
